News

In September 2006, Alnylam was awarded a federal contract providing the company with up to $23 million in funding over a four-year period to develop small interfering RNAs

In collaboration with Merck & Co, deforolimus is currently being studied in multiple clinical trials, both alone and in combination with other therapies, in patients with several different

Results from Phase I, Phase II and Phase III double-blinded clinical validation studies on prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson

These two patents are said to cover the basic composition of viral particles resulting from Lipid Sciences’s proprietary viral delipidation process. Lewis Meyer, president and CEO of Lipid

GlaxoSmithKline (GSK) conducted this review upon learning that the analysis undertaken by the D:A:D cohort had found an unexpected but potential association between highly active antiretroviral therapy (HAART)

The double-blind, placebo-controlled single ascending dose (SAD) trial evaluated the safety and pharmacokinetics of four doses of FV-100 in five cohorts of healthy volunteers (100, 200, 400, and

This second tranche of $15 million was funded by existing investors – Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures. Guy Macdonald, president and

Defend is a randomized, placebo controlled Phase III trial designed to enroll approximately 240 adult patients, age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. Defend

The settlement is expected to close by September 5, 2008. UCB will pay Eurand a total of $35 million, of which $25 million will be paid at closing,